Pegvisomant Pfizer/Sensus.
Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH receptor activation. This drug is now available in the US and Europe for the treatment of acromegaly.
Goffin
Vincent
V
Inserm Unit 584, Hormone Targets, Faculty of Medicine Necker, 156 rue de Vaugirard, 75730, Paris Cedex 15, France. goffin@necker.fr
Touraine
Philippe
P
D000172:Acromegaly / Q000188:drug therapy; D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003692:Delayed-Action Preparations; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D003692:Delayed-Action Preparations; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; C406545:pegvisomant